Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

07 janv. 2026 20h05 HE | Source: Direct Meds

Best Oral Peptides for Weight Loss: Injectable vs Sublingual vs Daily Pill – Direct Meds Consumer Analysis

January 2026 consumer analysis compares oral Wegovy, compounded sublingual semaglutide, and tirzepatide drops across pricing and access formats.
06 janv. 2026 21h10 HE | Source: Direct Meds

Best Peptides for Weight Loss 2026: Oral Wegovy Launch Expands GLP-1 Format Options as Telehealth Platforms Compare FDA-Approved vs Compounded Semaglutide Access

Oral Wegovy launch expands GLP-1 format options as Direct Meds telehealth platform compares FDA-approved vs compounded semaglutide pricing structures.
30 déc. 2025 20h57 HE | Source: Direct Meds

Best Wegovy Alternative for 2026? FDA Approves Oral Semaglutide as Patients Evaluate Compounded Telehealth Access — Direct Meds Examined as Verification Case Study

Industry analysis examines how patients verify telehealth GLP-1 platforms after FDA oral semaglutide approval. Direct Meds included as case study.
26 déc. 2025 23h34 HE | Source: Direct Meds

Direct Meds GLP-1 Medications Platform Maintains LegitScript Certification as New Year Weight Loss Interest Peaks Amid Compounding Regulatory Shifts

Analysis examines Direct Meds GLP-1 medications platform as LegitScript-certified telehealth option for compounded semaglutide and tirzepatide access.